GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Cyclically Adjusted PS Ratio

Cormedix (STU:19KA) Cyclically Adjusted PS Ratio : 216.67 (As of Sep. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cormedix Cyclically Adjusted PS Ratio?

As of today (2024-09-22), Cormedix's current share price is €6.50. Cormedix's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €0.03. Cormedix's Cyclically Adjusted PS Ratio for today is 216.67.

The historical rank and industry rank for Cormedix's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:19KA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 90.67   Med: 195   Max: 586
Current: 243.74

During the past years, Cormedix's highest Cyclically Adjusted PS Ratio was 586.00. The lowest was 90.67. And the median was 195.00.

STU:19KA's Cyclically Adjusted PS Ratio is ranked worse than
97.63% of 464 companies
in the Biotechnology industry
Industry Median: 5.355 vs STU:19KA: 243.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cormedix's adjusted revenue per share data for the three months ended in Jun. 2024 was €0.013. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.03 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cormedix Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Cormedix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Cyclically Adjusted PS Ratio Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 243.64 272.64 169.28 155.60 -

Cormedix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 142.81

Competitive Comparison of Cormedix's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Cormedix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cormedix's Cyclically Adjusted PS Ratio falls into.



Cormedix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cormedix's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6.50/0.03
=216.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Cormedix's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.013/132.5538*132.5538
=0.013

Current CPI (Jun. 2024) = 132.5538.

Cormedix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.009 100.428 0.012
201412 0.015 99.070 0.020
201503 0.006 99.621 0.008
201506 0.017 100.684 0.022
201509 0.005 100.392 0.007
201512 0.003 99.792 0.004
201603 0.005 100.470 0.007
201606 0.002 101.688 0.003
201609 0.005 101.861 0.007
201612 0.014 101.863 0.018
201703 0.005 102.862 0.006
201706 0.012 103.349 0.015
201709 0.004 104.136 0.005
201712 0.006 104.011 0.008
201803 0.001 105.290 0.001
201806 0.000 106.317 0.000
201809 0.017 106.507 0.021
201812 0.001 105.998 0.001
201903 0.006 107.251 0.007
201906 0.001 108.070 0.001
201909 0.002 108.329 0.002
201912 0.001 108.420 0.001
202003 0.003 108.902 0.004
202006 0.001 108.767 0.001
202009 0.003 109.815 0.004
202012 0.001 109.897 0.001
202103 0.002 111.754 0.002
202106 0.000 114.631 0.000
202109 0.001 115.734 0.001
202112 0.001 117.630 0.001
202203 0.000 121.301 0.000
202206 0.001 125.017 0.001
202209 0.000 125.227 0.000
202212 0.001 125.222 0.001
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 0.013 132.554 0.013

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cormedix  (STU:19KA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cormedix Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Cormedix's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix Business Description

Industry
Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Cormedix Headlines

No Headlines